China to soon launch Fruquintinib, its self-developed anti-cancer drug
Date: 2018-07-02   Author: Ojaswita Kutepatil  Category: #news

China to soon launch Fruquintinib, its self-developed anti-cancer drug

The China Food & Drug Administration has reportedly acknowledged an approval of the anti-cancer drug, Fruquintinib, for the treatment of patients with advanced colorectal cancer. Allegedly, the drug is likely to be approved by the year end and may hit the market soon.

According to reports, the anti-cancer drug is developed conjointly by Li Jin, an oncologist by profession & director of the Tumor Department at Shanghai East Hospital and Qin Shukui, associate head of the 81st PLA (People's Liberation Army) hospital and 28 domestic clinical drug research institutes.

According to the Journal of the American Medical Association (JAMA), the combined research by both the parties not only exhibited effective results in fighting colorectal cancer but also proved to be less toxic to humans.

Li revealed in a statement that the approval of the new drug will bring a ray of hope to the patients diagnosed with colorectal cancer and who have already undergone at least two chemotherapy treatment settings but are yet to see disease remission.

If reports are to be believed, the new drug could extend the life expectancy for over 9 months.

For the record, annually over 370,000 people are diagnosed with colorectal cancer in China and a majority of them are already in the last stages of the disease. Chemotherapy, in this regard is one of the most common treatment methods for colorectal cancer, however, it has shown very limited results on the late-stage patients.

Presently, China is the main producer of the generic anti-cancer drug, say sources familiar with the matter. The approval of the new drug Fruquintinib is set to hold importance as far as the country’s transition toward developing new drugs is concerned.

It has been reported that Shanghai East Hospital aims to develop minimum 30 new anticancer drugs every year and will be soon introducing 20 new clinical studies on anti-cancer drugs.



About Author


Ojaswita Kutepatil

Ojaswita Kutepatil

Ojaswita Kutepatil, a mechanical engineer by qualification, worked as a BDE and Technical Engineer before switching her profession to content writing. Currently, she works at AlgosOnline. as an Content writer, where she pens down write-ups pertaining to the market res...

Read More

More from Ojaswita


Post Recommendents

Asia Pacific Passive Fire Protection Materials Market will grow at 9.5% CAGR up to 2024
Author: Rahul Varpe

Based on the end-users, building & construction segment for passive fire protection materials market is projected to grow with CAGR of about 8.5% by 2024. This is attributed to strong persistence by regional regulatory bodies primarily in emer...


Tata Group in talks of acquiring a controlling stake in Jet Airways
Author: Ojaswita Kutepatil

Tata Group is reportedly inspecting Jet Airways’ books as the multinational corporation considers to grow its footprint in India’s growing air travel sector by potentially purchasing a stake in the cash-str...


Ring Main Unit Market is Projected to Reach USD 3 Billion by 2024
Author: Rahul Sankrityayan

Increasing investments in large scale renewable energy projects along with rigorous ongoing efforts toward the expansion of micro-grid network have significantly impelled ring main unit market commercialization. On account of the renewable energy ...